Rhythm Pharmaceuticals Inc RYTM:NASDAQ

Last Price$4.26Cboe Real-Time Last Sale as of 10:26AM ET 6/30/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.01(0.23%)
Bid (Size)$4.25 (313)
Ask (Size)$4.27 (1)
Day Low / High$4.17 - 4.26
Volume36.4 K

Sector Update: Health Care Stocks Finish Higher on Wednesday

4:10PM ET 4/06/2022 MT Newswires
Health care stocks continued to add their Wednesday advance, with the NYSE Health Care Index and the SPDR Health Care Select Sector ETF (XLV) rising 1.9% and 1.6%, respectively.

The Nasdaq Biotechnology index climbed 0.3%, reversing a midday decline.

In company news, Tilray Brands (TLRY) rose 3.1% on Wednesday after the cannabis producer reported a surprise fiscal Q3 profit, earning $0.09 per share compared with a $1.03 per share loss during the same quarter last year.

Celsion (CLSN) dropped 16.7% after the biotechnology company Wednesday plans a $7 million offering of around 1.3 million shares at $5.27 apiece, or 15.3% under Tuesday's closing price.

Rhythm Pharmaceuticals (RYTM) fell over 16% after the drug maker said it was modifying phase II and phase III testing of setmelanotide drug candidate to treat rare genetic diseases of obesity to focus on rare patient populations that it believes "have the highest likelihood of success."

BioXcel Therapeutics (BTAI) was little changed, giving back a more than 12% gain earlier Wednesday after saying the US Food and Drug Administration has approved its Igalmi sublingual film for the treatment of acute agitation associated with schizophrenia or bipolar I or II disorders in adults. BioXcel shares also were getting a boost from BoA Securities increasing its price target for the stock by $2 to $80.